25 November 2018 - Last spring, weeks before the new migraine drug Aimovig hit the market, the phone calls and email started stacking up — patients around the country were contacting the UCSF Headache Center, eager to get on the medication as soon as it became available.

Their enthusiasm was understandable. Aimovig was the first in a new class of drugs developed to treat migraines. It had been decades since any migraine-specific drug had come along, and soon patients would have three new drugs to choose from.

But in the months since the drugs have won approval by the U.S. FDA, actually getting the therapies to patients has proved challenging.

Read San Francisco Chronicle article